PROTALIX BIOTHERAPEUTICS INC (PLX)

US74365A3095 - Common Stock

1.27  -0.06 (-4.51%)

After market: 1.28 +0.01 (+0.79%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2020 2021 2022 2023 2024 2025
Revenue
YoY % growth
62.9M
15.01%
38.35M
-39.03%
47.64M
24.22%
64.619M
35.64%
EBITDA
YoY % growth
4.01M
144.07%
-19.34M
-582.29%
-11.92M
38.37%
N/AN/AN/A
EBIT
YoY % growth
2.71M
125.28%
-20.46M
-854.98%
-13.01M
36.41%
15.496M
219.11%
Operating Margin
4.31%-53.35%-27.31%23.98%
EPS
YoY % growth
-0.16
86.45%
-0.63
-293.75%
N/A0.11

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q4 / 23 Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24
EPS
Q2Q % growth
-0.03
63.93%
Revenue
Q2Q % growth
8.206M
-4.80%
EBITDA
Q2Q % growth
N/AN/AN/AN/AN/A
EBIT
Q2Q % growth
-1.586M
36.55%
N/AN/AN/AN/A

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth
-0.07 -0.03-0.04-177.23%
Q3 2023
Q2Q % growth
-0.04
42.86%
-0.070.0343.42%
Q2 2023
Q2Q % growth
0.21
290.91%
-0.040.25619.80%
Q4 2022
Q2Q % growth
-0.07
53.33%
-0.150.0853.80%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2023
Q2Q % growth
10.345M
-27.05%
7.716M2.629M34.07%
Q2 2023
Q2Q % growth
35.08M
300.91%
10.324M24.756M239.79%
Q4 2022
Q2Q % growth
8.62M
0.82%
6.181M2.439M39.46%
Q3 2022
Q2Q % growth
14.18M
17.68%
5.752M8.428M146.52%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% 0% 0% 0%
Revenue0% 0% 0% 0%